MINNEAPOLIS, Jan. 14, 2015 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, will release financial results for the fiscal
third quarter ended December 31, 2014
after the market close on Thursday, January
22, 2015.
The Company will host a conference call and webcast to discuss
these results on Thursday, January 22,
2015 at 4:30 p.m. Eastern Time
(3:30 p.m. Central Time).
Rob Kill, President and Chief
Executive Officer, and Brett
Reynolds, Chief Financial Officer, will host the event.
Individuals wishing to participate in the conference call should
dial 888-523-1225. No passcode is necessary. To access a live
webcast of the call, go to Uroplasty's website at www.uroplasty.com
and click on the Events Section of the Investor Relations page.
An audio replay will be available for 30 days following the call
at 888-203-1112 with the passcode 7560178. An archived webcast will
also be available at investor.uroplasty.com.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered
in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The
Netherlands and the United
Kingdom, is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent® PC Neuromodulation System, the
only commercially available, FDA-cleared system that delivers
percutaneous tibial nerve stimulation (PTNS) for the office-based
treatment of overactive bladder (OAB). OAB is a chronic condition
that affects approximately 42 million U.S. adults. The
symptoms include urinary urgency, frequency and urge
incontinence. We also offer Macroplastique®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952.426.6152
EVC Group
Doug Sherk/Brian Moore (Investors)
415.652.9100/310.579.6199
Janine McCargo (Business Media)
646.688.0245
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/uroplasty-to-announce-third-quarter-fiscal-year-2015-financial-results-on-january-22-2015-300020327.html
SOURCE Uroplasty, Inc.